The therapeutic landscape for non-alcoholic steatohepatitis (NASH) has undergone a dramatic transformation with Madrigal Pharmaceuticals' introduction of Rezdiffra (resmetirom), marking an unprecedented milestone in hepatic medicine. This revolutionary medication stands as the inaugural FDA-approved treatment specifically targeting NASH with fibrosis, fundamentally changing how clinicians...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek